A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Lulizumab pegol (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 17 May 2017 Planned End Date changed from 1 Mar 2018 to 31 Jul 2017.
- 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 30 Jul 2017.